The Delta variant of COVID-19 was detected back in April 2021 in India. It was particularly dominant in Maharashtra, Kerala and Madhya Pradesh. As a result, government regulations have tightened the restrictions and in many parts of these states, lockdowns have been observed in the last 2 months.
There was widespread scepticism regarding the efficacy of the Covaxin and Covishield vaccines against this new variant. However, a recent study has revealed that Bharat Biotech’s Covaxin is indeed quite effective against the new Delta Plus variant of the coronavirus.
Covaxin, which is essentially a whole-virion inactivated SARS-CoV-2 vaccine, was found to be effective against the earlier Delta variant. Even during the second wave, which was mainly caused by the Delta variant, this vaccine proved to be 65.2% effective in protecting vaccinated people from the virus. Studies had been conducted in a double-blind, randomized and multicentre phase 3 clinical trial which had shown that the mass inoculation drives using Covaxin had been highly effective in controlling the spread of the earlier Delta variant.
Since Covaxin had earlier proven effective against the Delta variant, it is highly possible that it has a similar potency against the Delta Plus variant. The recent study in question was conducted by the Indian Council of Medical Research and has been recently published in the online research repository known as bioRxiv. The study stated that the natively developed Covaxin of India has been deemed effective against the Delta Plus variant. It concluded that Covaxin has shown 77.8% efficacy against symptomatic COVID-19 which is a phenomenal breakthrough discovery since this gets one step further in flattening the curve.
Since there has been great confusion regarding the extent to which Covaxin can be effective against this new variant, this study has shed light on certain facts and helped put many vaccinated people at ease. It was earlier speculated that the Delta Plus variant, which contains a mutation of the K417N spike protein can probably escape the immune response generated by the vaccines. Virologists and doctors were anxious that this new variant could surpass the effect of antibody response, thereby rendering Covaxin ineffective. However, with this new study, vaccinations using Covaxin can continue throughout the country as it shows a modest level of efficacy against the Delta Plus variant as well.
While the efficacy of Covaxin against the original variant of COVID-19 was reported to be 81%, that of the Covishield was reported to be 90%. As a result, many preferred the latter over the former homegrown vaccine. However, with the emergence of new variants like the Delta and the Delta Plus, it is seen that the effectiveness of both Covaxin and Covishield have been reduced.
A study published in the New England Journal of Medicine suggested that AstraZeneca’s Covishield, which has similar properties to that of Covaxin, is 67% effective against the new Delta and Delta Plus variants. In comparison, India’s very own Covaxin is about 65.2% effective, meaning there is not much difference between the efficacy of both.
COVID-19 vaccinations have been faced with mixed reactions from people along with typical rumours of being a placebo. However, such is usually the case with any medical or scientific breakthrough in its initial stages. As someone who has already been vaccinated, you must remember that these vaccines have undergone extensive human trials by now and new studies are being published frequently about their increased efficacy. Therefore, if you have already been vaccinated, you can rest assured that your vaccination has not been in vain.
Another factor to consider is the protection that vaccines offer despite not having a 100% prevention rate. As late as Jan 2022, vaccines were shown that not only do all vaccinations provide protection against severe symptomatic disease, it also protects against hospitalisation for Covid-19. In turn, several studies have shown that hospitalisation and death rates from Covid-19 are much lower in those who are vaccinated vs those who aren’t. Additional data coming in also shows that a booster shot (a third shot of the vaccination) also adds to this type of protection.
Even though these new studies have proven that Covaxin or any other COVID-19 vaccine for that matter, provide a decent amount of protection against the virus, none of them has 100% efficacy. Therefore, it is important that despite being vaccinated, we still follow all necessary COVID-19 protocols in order to prevent any future waves of this virus.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
2022 comes with the hope of a better and healthier future for us all. India is on its way towards complete vaccination. Under-18 vaccination too has started. This means we are one step closer to defeating COVID-19. But that does not mean we should drop all precautions. New variants and even hybrid infections are on the rise. You need not worry as long as you are cautious. In this context, it is essential that we all learn a little more about Flurona, which has been making headlines all over the world. The start of 2022 has been marked with fresh news about the emergence of two new threats. We already know that a new wave brought on by the Omicron virus (first detected in South Africa) is right around the corner unless we are all very cautious. But it has emerged that there could be another threat looming in the distance. The new danger that has got scientists anxious is flurona. What is flurona and what is it capable of doing? Read on to find out.
Flurona was found in the body of a pregnant woman in Israel when she was hospitalized to give birth.
Flurona is not a strain of COVID-19. It is actually a term used for the illness caused by 2 infections at the same time in the same person- one being the seasonal Flu and the other being COVID-19. That means, her body was harbouring both the seasonal flu virus and the coronavirus at the same time. It is a case of double infection.
She tested positive for both the Flu and COVID and the diagnostic tests were carried out more than once for confirmation. Her symptoms were mild. The woman had not been vaccinated for COVID-19. Because her symptoms are mild, she will be discharged soon as per news reports.
The infection thus caused is also a viral infection and contagious. Scientists believe this happened because this is the Flu season and the human body is capable of sustaining both kinds of viruses at the same time.
The symptoms of flurona are the same as the Flu or COVID-19 because it is also an upper respiratory tract infection. It triggers fever, sore throat, body ache, fatigue and breathing difficulty.
Will flurona be more dangerous than the strains of COVID-19?
This is too early to state anything about the severity of this dual infection. With more information and studies, we are likely to receive a clearer picture of the spread and threats associated with flurona.
COVID appropriate behaviour can save us from exposure to both infections. Do not forget these points-
In the upcoming days, we cannot let caution and care slide. Omicron is already here and delta has not gone yet. Life must indeed go on, but we must adopt every precaution possible. Masks, sanitisers, social distancing and following government circulars on safety should once again be part of our lives. A lit bit of caution never hurts anyone. It can in fact save lives. The safety of each and everyone is our collective responsibility at this time. Let’s do our bit to reduce the transmission of Covid infection.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
Amidst alarming news of COVID-19 cases increasing in India due to the Omicron variant, there is a ray of hope in the New Year with the government rollout of vaccines for children, frontline workers and senior citizens. The new vaccination drive which is to begin from 3rd January 2022 for teens aged 15-18 years signifies that every cloud has a silver lining.
To know more about the current scenario, what the government is planning and what you should do to stay safe read the article below.
Addressing the country on 25th December 2021, the honourable PM announced that The Drug Controller General of India (DCGI) has approved the emergency use of the indigenously developed Covaxin for immunising young adults. Aside from Covaxin, ZyCoV-D developed by Zydus Cadila has also been authorised for emergency usage. However, the vaccination drive as of now will only cover children in the 15-18 years age bracket and Covaxin will be administered to them. Designed as a precautionary measure to protect the future of the Nation from the impending harm of the new variant, guardians as well responsible youths are urged to get their children and themselves registered respectively on the Co-WIN Portal.
As of now, the authorised COVID-19 vaccine for under 18 in India is slated to be only for Covaxin.
Frontline workers i.e., employees who have to be physically present at their jobs such as doctors, fire-fighters, policemen and other kinds of industry professionals were the first to get their jab last year when the vaccination drive started followed by senior citizens (with co-morbidities). To make sure that everyone is safe in the face of the omicron virus surge, the Government has announced and emphasised that these two groups will be once eligible for a booster vaccine dose called a precaution dose from January 10th 2022. To get the jab, registrations are required to be made on the portal once again. For safety concerns, senior citizens are advised to go ahead with the booster dose upon confirmation from their respective healthcare providers.
As of reports released on 3rd January 2022, the Union Health Ministry announced that the Omicron variant cases were 1,700 in the country with an infection radius of 23 states and union territories. Delhi itself recorded 84% of new infections in the last few days. Currently, Delhi is functioning with a ‘yellow alert’ category of restriction under which educational institutions, gyms, theatres and shops involved in the trade of non-essential items are meant to stay shut until further notice.
However, as per studies conducted by doctors, the Omicron variant is said to only bring about mild infections with little requirement for oxygen concentrators and hospitalization, unlike the Delta variant.
The trend shows that those without vaccination are likely to suffer a more painful infection as opposed to those being doubled vaccinated.
Another trend being noticed is that in most cases of the infection, the individual is asymptomatic, meaning that he/she wouldn’t know that they are infected and will unknowingly spread the viral infection when in close contact with others. Keeping this fact in mind, civilians are being asked to be cautious and follow all COVID-19 appropriate behaviour. This includes limiting going out in public spaces and spending the rest of the winter season in a low key manner. As per news reports, the festive season during December was one of the main drivers behind the surge in Europe and also why COVID-19 cases are increasing in India and so now there is a necessity to salvage the situation before it goes totally out of hand.
Although the Omicron variant is spreading quite fast, the good news is that India will see a surge by the end of January which means that the lifespan of this infection is going to be short-lived. In the meanwhile, it is advised that you get your children and elderly family members vaccinated and follow COVID-19 mandates at all times. Follow all safety precautions in order to save yourselves and others from the risk of exposure to COVID-19 infection.
Disclaimer:
The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
The Omicron wave is looming and India must prepare itself to deal with another possible outbreak, this time triggered by the new COVID-19 variant called Omicron. But before you start to despair, let us tell you that you can keep yourself safe from it. And it starts with awareness. COVID cases are indeed increasing in India. But why? Is it just because Omicron is very contagious or is something else behind it? Read on to find out.
The second wave that was caused by the Delta had abated by October. India started registering very few cases since October. Naturally, most of us thought that the worst of COVID-19 has passed.
But in late November 2021, South African scientists identified a new variant which was named Omicron or B.1.1.529. This is by far the most infectious COVID-19 variant and very soon Omicron cases began to be reported in other countries of Africa, Europe and the Americas.
In early December, Omicron reached India. By December 31st, India crossed the 16,000 Covid cases mark, for the first time in 4 months. With 16, 764 cases being reported on 31st December, India has logged the highest case count since October. The number has been rising steadily since then. According to the Union Ministry of Health, the Omicron case tally, for now, is 1700.
Densely populated states and cities naturally rank high. Maharashtra and the NCT have more Omicron cases than the rest of the country. By December 31st, Delhi recorded a 42% increase, and Mumbai a 46% increase from the previous day.
The positivity rate, for now, is 1.87%. According to WHO, this rate should be below 5%. Once the 5% mark is crossed, containing the spread becomes immensely challenging.
Maharashtra, the NCT and Karnataka hospitals have been admitting a steady stream of COVID-19 patients, the number being higher than that of the last few months. The good news is most of these people are recovering well. This is in keeping with what has been observed in South Africa and the UK.
So far, there are no reports on the severity of illness in cases of COVID-19 caused by omicron among the vulnerable population (babies and people with comorbidities).
One reason why COVID cases are increasing in India is that Omicron is highly transferable. As soon as it arrived in India, experts knew that it would spread and there would be a risk of the third wave. Caution was sounded.
However, not all cases of COVID-19 being recorded are triggered by Omicron. So why did COVID cases abate and then pick up again?
The most obvious reason is our complacency. As soon as the second wave receded, people began to relax COVID-19 precautions. Even the previous variants like Delta are still spreading and causing infections. When we do not mask up, sanitize or wash up, we make ourselves and everyone else vulnerable to an infection caused by any COVID-19 variant.
The increase in travelling and gatherings during the winter festive season has been a contributing factor in the spike of Covid cases everywhere.
Also Read: What Precautions to Take Against Omicron Variant?
The Union Government and state governments (such as West Bengal) have already released or devised new COVID-19 circulars outlining the restrictions that have or will come into force. Common guidelines you may expect include operating trains and metros at 50% capacity, quarantine zones, work from home wherever possible, 50% attendance in offices, night curfews, restriction of flights, etc.
Now the onus is on every one of us to be cautious. Only by being prudent will we be able to keep ourselves safe from Omicron, the other variants of COVID-19 and from the third wave. Let us not be complacent just because Omicron is likely to be less dangerous than the other variants. The threat is serious. The third wave is at our doorstep and for the next few weeks, we must all observe every COVID-19 precaution.
Studies predict that unless we are careful, the third wave caused by Omicron may result in 150% more cases than the second wave. Such a caseload would overwhelm our healthcare services.
For age 15 to 18 COVID vaccines are being administered now. So please get your child registered for the vaccine. If you are yet to receive full vaccination, make sure that you get both doses as soon as possible. Vaccination can save lives.
Also Read: Is Covishield Effective Against Omicron Variant?
Let us all recall the horrors of the second wave. It is fresh in our collective memory. Let us make sure that there is no repeat of that. For the sake of our loved ones, and our country and world at large. We can all try to be cautious in the upcoming days. Cancel your holiday plans (if possible), and avoid crowds because health is more important right now than enjoyment.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
The Serum Institute of India (SII) sought and received approval from the World Health Organisation on the 17th of December, 2021 for the emergency use of Covovax. SII is one of the largest vaccine manufacturers in the world and WHO approved the Emergency Use Listing (EUL) of the COVID-19 vaccine Covovax, which was developed under the licence of Novavax. This is the recent vaccine associated with India, that has been approved by the WHO, the other two being Covaxin and Covishield. This vaccine has been approved for immunisation of individuals who are 18 years and above.
The fight against COVID-19 is ongoing and vaccinations for the entire population is the need of the hour. When vaccines against COVID-19 were first introduced to the world, many third world nations like India suffered from vaccine shortages. The manufacture of Covaxin (India’s first indigenous vaccine) and Covishield (the Indian version of Britain’s AstraZeneca) were major milestones for the efforts to vaccinate India.
The approval of Covovax in India by the WHO is an important milestone because more people can now get vaccinated (especially in lower-income nations). This indicates that there are now 9 (Covovax being the 9th one) COVID-19 vaccines that can help us stay protected from the virus. The approval of the vaccine is a positive indicator of the safety and protection of the people from SARS CoV-2.
The approval of the Covovax vaccine by the WHO is a strong indicator of its efficacy and safety. It is important to know whether a vaccine is showing effectiveness or not. Covovax has been developed using the technology of the Novavax vaccine, which is effective in providing protection against the mutated strains of the COVID-19 virus. Since the Covovax vaccine has been deemed safe for use, it means that more people can now get vaccinated and stay protected against mutated strains as well. A projected third dose can increase the antibody count by up to 4-6 times and provide resistance against the delta variant. Studies about the protection against the omicron variant are still ongoing.
SII CEO Adar Poonawalla has announced plans for the launch of Covovax jabs for children too. He plans to launch a vaccine for children from the age of three. Although children have not faced any deadly effects of the virus, vaccinating them ensures a safety net for them.
COVOVAX is the protein-based COVID-19 vaccine option, with demonstrated efficacy and a well-tolerated safety profile, to be made available through the COVAX Facility said CEO of Serum Institute of India, Mr Adar Poonawala. The Covovax vaccine uses spike proteins to help the immune system adapt to combat the virus and create antibodies.
Covovax requires storage between the temperatures of 2 °C and 8 °C, therefore existing cold chain supply lines for vaccine transport can be used for this vaccine as well.
Clinical studies show a 96.4% efficacy against mild or severe COVID-19 infection. The Covovax vaccine has a very strong safety profile and the booster shots are deemed to be more effective. Although more study is required to understand the vaccine’s efficacy against the Omicron variant. However, the INSACOG (Indian SARS-CoV-2 Consortium on Genomics), does believe that there are high chances that Covovax will receive approval as the booster shot that we may all need.
Children need the COVID-19 vaccine as much as adults do because they are returning to schools and colleges and they are vulnerable without the protection offered by vaccines. So can Covovax be administered to children? According to Poonawalla, Covovax is safe and can offer the required protection to all children down to three years of age.
The approval of Covovax by the WHO is a boost for India’s vaccination drive. It is also a positive indicator that studies to understand and counter the COVID-19 virus are being effective. Serum Institute of India also plans to introduce a vaccine for children based on Covovax. You can stay assured that Covovax is an effective measure to protect yourself from mutated strains of the virus. It is important for everyone to get vaccinated, follow covid-appropriate behaviour and maintain a safe distance from others to reduce the risk of exposure to COVID-19.
With 2021 coming to an end, a new COVID-19 variant has posed a threat to the resumption of normalcy. This variant, the B.1.1.529, popularly known as the Omicron variant, is now being studied closely by scientists, medical practitioners, and medical officials. Although the number of cases of Omicron detected in India are just above 100 now, there may be a good chance of it increasing exponentially in the next couple of months.
While the Omicron variant has already made its entry into India, it is supposed to have originated from South Africa, and officially been identified in Botswana.
Soon after the identification of this new variant of COVID-19 by a team in Botswana headed by Dr Sikhulile Moyo, the World Health Organisation (WHO) did not hesitate to classify it as a Variant Of Concern (VOC). The reason that the WHO has classified this variant of COVID-19 as a VOC is because of the high number of mutations and its rate of transmission. Soon after, many other countries also identified this new variant affecting their population.
Do not hesitate to get an RT-PCR for diagnosis of Covid even if you experience mild symptoms and no fever. Early identification, self-isolation and treatment can play a significant role at this time.
Although the most recent data suggests that the Omicron variant has much higher transmissibility than even the previously deadly Delta variant, it does not seem to be overloading hospitals yet. The latest data points out that even though more than 50,000 cases have been reported in the last couple of weeks in the origin country of this variant, the number of deaths reported due to Omicron is significantly low.
This naturally poses questions about the transmissibility and the severity of this mutation of the Coronavirus.
Based on statistical data from South Africa, the epicentre of this new mutation, it has been assumed that the Omicron variant is 3 times more capable of infecting other people as compared to the delta variant. Moreover, the rate of increasing cases has surpassed that of the previous 3 waves of COVID-19 as well.
At the other end of the globe, Japanese researchers have been able to confirm that the Omicron variant is 4.2 times more transmissible than previously reported variants. Apart from the countries in the African continent, this new mutation has penetrated the populations of the UK and other European countries as well. More than 77 countries have reported Omicron cases so far. There can also be a case that some countries may have undetected cases of Omicron spreading. What is more alarming is the fact that the number of cases has been seen to be doubling every 1.5 to 3 days.
Also read: Chamoy Benefits: A Research-Backed Health And Flavour Guide
Most patients in the affected regions of Africa have reported mild to severe headaches, scratchy throat, body aches and a constant sense of fatigue. This is a stark contrast to the symptoms reported by patients during the Delta wave (which included fluctuating pulse rates and respiratory trouble). However, it is important to note that it is too early to comment anything on the presentation and severity of this variant. There are reports on cases with severe symptoms and fatal consequences as well.
World Health Organisation says not to take this variant lightly because-
A high number of mutations in the spike protein of Omicron has raised a question on the efficacy of existing Covid vaccines. There are no studies so far to show the inefficiency of vaccines so far. There can be some variation in the efficacy but vaccines are definitely going to help. Also, delta is still the dominant variant so irrespective of the variant type we need to get ourselves vaccinated and follow steps to reduce our risk of exposure.
Also Read: Is Covishield Effective Against Omicron Variant?
While the transmissibility of this new variant currently seems much higher than any previous variants of the Coronavirus, it is important to remember that timely medical intervention is the key. And more important is to prevent the spread of COVID-19 by getting vaccinated and following all the safety measures sincerely. On a positive note, we are all well versed with Covid-appropriate behaviour by now and can play a heroic role in reducing the spread of Covid infections in our region.
Whatever it may be, it is always important to eat a nutritious diet rich in antioxidants and exercise regularly, to help boost your body’s natural immunity. This can, to a great extent, help your body fight off the infection and suppress any life-threatening symptoms.
Read More: Precautions to Take Against The Omicron Variant
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
COVID-19 has impacted people’s lives for quite some time now. It severely affects people with different comorbidities.
What are the main causes of concern for people with diabetes with respect to COVID?
The major problem areas or risk factors of COVID in people with diabetes and of COVID related to diabetes are:
COVID infection, due to the toxicity of the virus, is dangerous and can be fatal. Uncontrolled diabetes amplifies the problem if a person gets COVID.
Uncontrolled blood sugar levels increase COVID risk for people with diabetes. This means that if a person has diabetes and gets infected with COVID, the COVID complications can become severe and the pace of COVID disease progression is faster. This is further worsened if the diabetes is uncontrolled. COVID complications with uncontrolled diabetes can become a cause of mucormycosis.
The severity of COVID in people with diabetes is due to uncontrolled blood sugar levels. As a known complication of diabetes, people with diabetes are at a greater risk of having a blood circulation problem and inflammation in the body.
Diabetes is known to cause long-term damage to nerves, blood vessels, kidneys, and other organs. Generally, people with diabetes are also prone to inflammation of cells and tissues. One such condition is called Cellulitis. Such conditions are listed as criteria for a person being classified as a high-risk patient. These conditions can increase the risk of COVID in people with diabetes.
However, it does not imply that if a person has diabetes, the chances of contracting COVID can increase. It just increases the chances of severe infection after contracting COVID. The impact of COVID in people with diabetes can vary as per the type of diabetes.
It also depends on other comorbidities or conditions, such as
– Dyslipidemia (high cholesterol or triglyceride levels)
– High Blood Pressure
– Blood circulation problems, clots in the arteries
– History of angioplasty or bypass surgery
These comorbidities or associated conditions, besides type-2 diabetes, can increase the COVID complications and severity of the infection in people with diabetes.
No, even if diabetes is under control, COVID risk for people with diabetes continues to be present since it causes a fluctuation in blood sugar levels.
For a person with controlled diabetes maintaining normal blood glucose levels, COVID infection may offset the control. The body’s inflammatory response to the virus causes fluctuations in blood sugar levels.
Normally, for a person who gets COVID infection, the following parameters are closely observed and monitored:
– Body temperature (fever)
– Respiratory rate
– Oxygen Saturation (SpO2)
For COVID infection in people with diabetes, monitoring blood sugar levels is vital. There will be fluctuations throughout the day starting from the time of the infection. Blood Glucose monitoring via the machine at home is sufficient to keep a check. One must communicate the readings to the doctor for records.
Even if the diabetes is in check with routine oral medication, there is a possibility that the blood sugar fluctuations due to COVID may require your diabetologist to start insulin therapy. This insulin is warranted to keep the blood glucose levels in control during the COVID infection with minimal side effects during sick days. After recovery and complete healing, the insulin dose may be stopped by your doctor.
So as long as someone with diabetes does not contract COVID, there is no problem?
No, not necessarily. Even without contracting the actual virus, COVID has created trouble for people with diabetes. While it sounds odd, there is an indirect impact of the Global pandemic for those with diabetes. COVID can also induce hyperglycemia in people without previously diagnosed diabetes and increase the risk of critical diseases. There are two distinct problem groups owing to the COVID pandemic.
The COVID pandemic related lifestyle changes can be summarised as follows:
· Financial instability
· Risk of contracting the infection
· Lockdown and the restrictions with it
· Family health and security
· Death of near and dear ones
· Lockdowns meant no movement and home isolation.
· Work From Home (WFH) meant no travelling to the office.
· No exercise as gyms and parks were closed.
· Steroid medications were used as an important part of treatment for severe COVID-19 in many patients. Some patients even self-medicated themselves with these medicines during COVID infection. Steroids increase the risk of diabetes especially when given in high doses or for a long duration of time.
All these three factors directly affect the body’s metabolism which impacts the way your body processes sugars and reflects on blood glucose readings.
The best possible solution for decreasing the COVID risk in people with diabetes is to maintain sugar levels in the healthy range, follow COVID-appropriate behaviour and get the COVID vaccine. The COVID vaccine for people with diabetes will directly reduce the severity of the infection and the impact on people’s health.
The COVID vaccine is safe, and as more people take the COVID vaccine, the severity of the disease’s impact will decrease. Subsequently, it will lead to reduced restrictions and lockdowns, which will provide the opportunity for people with diabetes to take better care of their health. But, people with diabetes and other comorbidities must consult their doctor before taking the vaccination.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
This year, India and the world have been going full throttle to vaccinate people and immunize the population against COVID-19. Two shots of all the approved COVID-19 vaccines are highly effective, safe and teach your immunity to protect you from the coronavirus.
However, recent research has thrown light on an uncomfortable fact. There are thoughts that COVID vaccine efficacy starts to dwindle a few months after the second shot is administered. For example, Pfizer efficacy drops to 77% after 4 months and Moderna efficacy remains 92% for about 5 months after which it may start declining. Antibody levels drop and does this mean, your immunity against COVID-19, especially more dangerous variants like Delta declines?
In this context, the medical community is discussing the importance of the COVID-19 booster shot. This is where the ‘3rd dose’ of the COVID vaccine comes into play.
Booster shots are the same vaccines that are being administered to fight COVID-19. Since antibody levels become quite low about 6 months after complete vaccination, booster shots can amp up the waning immune system. Research has also revealed that when people are given mRNA booster shots, then their immunity can increase up to 10 times! You will need lots of antibodies to shield you from Delta or any other highly contagious COVID variant.
This depends on how long the vaccine maintains its efficacy in your body. Some vaccines continue being highly effective up to 6 months after the 2nd dose whereas some start losing their effectiveness after about 4 months. As soon as the antibody count starts to drop, it will be time to get booster shots.
Eventually, everyone will possibly need booster shots to give a boost to their flagging immunity against COVID-19. But, as with the rollout of the vaccination programme, there will be priority groups who will be first in line to the booster shots:
Many countries have announced booster shots for selected populations. As of now, there is no such declaration about the third dose of the COVID-19 vaccine in our country. It is fair and essential to focus on the completion of the two-course vaccination drive going at present and then plan and prepare for the third dose if established vital by studies.
Until the Union government and the state governments come to a decision about the execution of the 3rd dose of COVID-19 vaccines, you can’t really avail of the booster shots. In the intervening time, make sure you get both the first and second shots of the vaccine and follow COVID-appropriate behaviour to keep yourself and the community safe.
Also Read: Omicron Variant & Vaccine Efficacy
There are limited studies and data on the long-term efficacy of vaccines. Some experts also opine that one should not worry about the decline in the number of antibodies after both doses of the vaccine because your immunity keeps a memory of the response needed and is capable of producing more antibodies when required. However, we need more studies and data to confirm this scenario. Till the time all you can do is to get both shots of vaccine and stay calm but not careless. The threat of COVID-19 has not gone away. Even if you are fully vaccinated, remember, there is still a possibility that you may contract COVID-19 unless you are careful. So, continue wearing masks, avoid crowded places, sanitize your hands and wash up thoroughly after coming home.
Also Read: Omicron Variant: Risk & Precautions
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
Covaxin – Is It Safe For You? Read To Know The Truth
The vaccination drive in India is progressing with great momentum. However, some people are still puzzled if they should take a shot of it or not. Well, the skepticism is totally understandable. Though the vaccines have been prepared in a haste but it has been studied well and thus has been approved by the government of India.
Covaxin is a COVID-19 vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). Covaxin has shown an 81% (interim 3rd phase trial results) efficacy rate against COVID-19 disease. ICMR even found Covaxin to be effective against the Delta variant of coronavirus
However, the vaccine manufacturers have issued an advisory people must go through before they take the shot.
The vaccine manufacturer has clearly stated that people who have a weaker immunity or are taking a medicine that impacts their immune system should not take the shot.
Bharat Biotech has released a fact sheet suggesting who else shouldn’t take Covaxin:
Moreover, people who have taken a shot of some other COVID-19 vaccine should also not take Covaxin.
Notably, before the vaccination drive was not launched, the government had said that people who are on immuno-suppressants or have a weaker immunity could take the vaccine but it might not turn out to be very effective. It is worth mentioning that people undergoing chemotherapy, HIV treatment or taking steroids are immune-suppressed.
Central Drugs Standard Control Organisation (CDSCO) has authorized Bharat Biotech for the restricted use of Covaxin under clinical trial mode. It means that the people, who are on the priority list prepared by the government-appointed panel, will be covered under this program.
It is the responsibility of the respective state governments to inform the individuals who are in line to get the vaccine. The people who are on the priority list have been given the option to receive or reject the vaccine administration at the government-specified booths.
So far, about eight lakh people have been vaccinated in India, and the authorities have seen only 580 cases of adverse effects on the patients. There also have been two deaths, in Uttar Pradesh and Karnataka but those were completely unrelated to the vaccine.
According to the official figures, only 0.18% of cases have resulted in adverse events following immunization (AEFIs), of which only 0.002% resulted in hospitalization.
Bharat Biotech has also defined the possible side-effects (mostly mild), that you may experience post-vaccination. Have a look:
The other adverse effects may include:
The government has set up specific booths for vaccinations, where they have appointed health experts, who will observe the patients for 30 minutes after vaccination to observe any serious side effects if they occur.
Bharat Biotech in its fact sheet has also confirmed that the recipients of the vaccine will be a part of a three-month follow-up program, in which designated government officials will track the development of any health issues in them.
In case, anyone develops any serious health conditions, they will get medically recognized standard care at a government facility. The person will also get compensation for developing many serious health issues.
The document further states that the clinical efficacy of Covaxin is yet not established, as it is still in the Phase 3 clinical trial stage. Hence, people who receive it are still advised to follow all the COVID-19 related precautions diligently.
People who are next in line to get Covaxin or any other COVID-19 vaccine must disclose their medical history to the vaccinator before vaccination to avoid any chances of adverse effects. Moreover, looking at the AEFI rate, people with a healthy immune system may take a sigh of relief.
Immunity is what it takes for you to be healthy or not healthy.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
Due to the combined efforts of the healthcare workers, government functionaries and most importantly, the people of the country, India can finally smell victory against the COVID-19 pandemic.
Yes, this is true as many epidemiologists and virologists are believing that India is expected to reach the endemic stage by the end of 2022.
You probably would be thinking that endemic means that the virus would no longer exist in the country. Well, unfortunately, this is not going to happen in the near future.
Endemic refers to a disease outbreak that stays within a specific area at a particular time and the authorities of the region would be able to beforehand estimate the rate of disease spread, transmission and severity of the outbreak. These outbreaks can be frequent but the chances of an extremely severe outbreak are less likely.
This means that fewer people would require hospitalisation and severe cases will also be a rare occurrence.
Speaking about the condition of the pandemic in India, Health Secretary Rajesh Bhushan recently said that the country was seeing an overall decline in the number of cases in most parts.
The health officials are closely monitoring the chances of the emergence of new variants while the COVID-19 related restrictions are being eased. The country is still facing local outbreaks, especially in Kerala, a state that is accounting for most of the cases on a daily basis.
The caseload of Kerala is consistently increasing as one in every five samples tested in the state are coming out positive. Back in early August, one in every eight samples was coming out positive. The state alone accounts for more than 60% of new daily cases in the country.
Explaining the same, the National Institute of Immunology scientist Vineeta Bal commented that the country will keep witnessing some hotspots in different parts depending upon the seroprevalence status, vaccination coverage and adherence to social distancing norms. The frequency of such occurrences will reduce as soon as the vaccination coverage improves across the nation.
The World Health Organisation (WHO) chief scientist Soumya Swaminathan recently stated that India is at or approaching the endemic stage.
She, while cautioning that things can change unexpectedly in a pandemic, specified that the country will still keep noticing small outbreaks in a few parts where the vaccine coverage is low.
Swaminathan also pointed out a mass blood sampling study that showed 65% seroprevalence for coronavirus in Indians. Seroprevalence represents the level of antibodies in the population of a particular country.
Seroprevalence coupled with extensive vaccination drives is expected to provide good protection against a severe third wave, which has been in talks ever since the brutal second wave subsided after wreaking havoc around the country.
She, however, pointed out that the things that may compromise the level of protection against the third wave are the appearance of the new variant and the duration of protection provided by the current set of vaccines. These possibilities can be handled through constant and rigorous surveillance.
The experts believe that India is not going to experience yet another aggressive wave of COVID-19 as a serological survey conducted by the Indian Council of Medical Research (ICMR) showed that two-third of the population of the country has antibodies against the virus.
It was a nationwide survey conducted by OCMR in June and July 2021 and involved a total of 29,000 participants, including 8,691 children, aged between six and 17 years. Even half of the children were found to be seropositive, which clearly meant that they were exposed to the virus.
The level of seropositivity was initially only because the person had been infected earlier but now vaccinations are also one of the reasons for that.
The director of the National Center for Disease Control Sujeet Singh has also said that despite the pandemic having defied most of our predictions, we will be entering the endemic stage within the next six months.
After about a couple of years of consistent fear, India is finally looking to be on the verge of a victory against COVID-19. While being hopeful, the experts have appealed to the people around the country not to loosen the guard against the virus. We should keep following the norms of social distancing and wearing a face mask every time we step outside. More importantly, we should get vaccinated at the earliest to achieve the seroprevalence the experts are talking about.
Disclaimer: The information included at this site is for educational purposes only and is not intended to be a substitute for medical treatment by a healthcare professional. Because of unique individual needs, the reader should consult their physician to determine the appropriateness of the information for the reader’s situation.
Next Page »« Previous Page